Nuveen Asset Management’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2024
Q4 | $3.54M | Sell |
414,104
-88,468
| -18% | -$756K | ﹤0.01% | 2138 |
|
2024
Q3 | $4.37M | Buy |
502,572
+85,799
| +21% | +$746K | ﹤0.01% | 2051 |
|
2024
Q2 | $2.85M | Sell |
416,773
-796,672
| -66% | -$5.45M | ﹤0.01% | 2210 |
|
2024
Q1 | $11M | Buy |
1,213,445
+200,902
| +20% | +$1.83M | ﹤0.01% | 1531 |
|
2023
Q4 | $4.52M | Buy |
1,012,543
+1,505
| +0.1% | +$6.71K | ﹤0.01% | 2039 |
|
2023
Q3 | $3.17M | Buy |
1,011,038
+91,436
| +10% | +$287K | ﹤0.01% | 2094 |
|
2023
Q2 | $4.75M | Buy |
919,602
+726,569
| +376% | +$3.75M | ﹤0.01% | 1940 |
|
2023
Q1 | $1.02M | Sell |
193,033
-18,127
| -9% | -$95.5K | ﹤0.01% | 2608 |
|
2022
Q4 | $594K | Sell |
211,160
-46,102
| -18% | -$130K | ﹤0.01% | 2837 |
|
2022
Q3 | $1.07M | Sell |
257,262
-90,835
| -26% | -$377K | ﹤0.01% | 2725 |
|
2022
Q2 | $1.4M | Buy |
348,097
+20,278
| +6% | +$81.5K | ﹤0.01% | 2622 |
|
2022
Q1 | $1.67M | Sell |
327,819
-61,729
| -16% | -$315K | ﹤0.01% | 2587 |
|
2021
Q4 | $2.42M | Buy |
389,548
+61,028
| +19% | +$380K | ﹤0.01% | 2477 |
|
2021
Q3 | $3.47M | Buy |
328,520
+67,812
| +26% | +$715K | ﹤0.01% | 2413 |
|
2021
Q2 | $3.7M | Buy |
260,708
+5,757
| +2% | +$81.6K | ﹤0.01% | 2402 |
|
2021
Q1 | $4.18M | Sell |
254,951
-345,720
| -58% | -$5.67M | ﹤0.01% | 2247 |
|
2020
Q4 | $12.4M | Buy |
600,671
+353,949
| +143% | +$7.33M | ﹤0.01% | 1551 |
|
2020
Q3 | $1.88M | Buy |
246,722
+28,488
| +13% | +$217K | ﹤0.01% | 2414 |
|
2020
Q2 | $1.82M | Buy |
218,234
+76,485
| +54% | +$637K | ﹤0.01% | 2375 |
|
2020
Q1 | $701K | Buy |
141,749
+8,261
| +6% | +$40.9K | ﹤0.01% | 2651 |
|
2019
Q4 | $527K | Sell |
133,488
-58,343
| -30% | -$230K | ﹤0.01% | 2896 |
|
2019
Q3 | $583K | Buy |
191,831
+65,541
| +52% | +$199K | ﹤0.01% | 2892 |
|
2019
Q2 | $556K | Buy |
+126,290
| New | +$556K | ﹤0.01% | 2959 |
|